세계의 신경유전학 검사 시장 예측(-2030년) : 유형별, 최종 사용자별, 지역별 분석

According to Stratistics MRC, the Global Neurogenetic Testing Market is accounted for $616.7 million in 2023 and is expected to reach $1372.1 million by 2030 growing at a CAGR of 12.1% during the forecast period. Neurogenetic testing involves examining an individual's genetic makeup to identify specific genetic variations associated with neurological conditions. Its uses include diagnosing neurological disorders, assessing risk factors and guiding personalized treatment plans, leading to more targeted and effective healthcare interventions.

According to a WHO report, the European region contributes 11.2% of global burden of neurological disorder followed by Western Pacific region with 10%.

Market Dynamics:

Driver:

Rising prevalence of neurological disorders

The growing recognition and understanding of conditions like Alzheimer's, Parkinson's, and various neurodevelopmental disorders prompt a heightened demand for accurate and early genetic testing. Advances in neurogenetic testing provide a window into the genetic predispositions and risk factors for these conditions, facilitating early diagnosis and precise treatment planning. As these disorders gain prominence and medical understanding evolves, the need for effective neurogenetic testing becomes pivotal in tailoring interventions, enabling better management, and potentially averting or delaying the onset and progression of these challenging neurological conditions.

Restraint:

High costs associated with testing and limited accessibility

The complex nature of genetic testing methods, coupled with the need for specialized equipment and expertise, contributes to elevated testing costs, making these services unaffordable for many individuals. Additionally, limited accessibility to advanced neurogenetic tests, especially in underprivileged or remote regions, restricts the reach of these crucial diagnostic tools. As a result, disparities in access to cutting-edge healthcare solutions persist, preventing many from benefiting from early diagnosis, personalized treatment, and risk assessment for neurological conditions.

Opportunity:

Increasing research and development

Ongoing advancements in genetic testing technologies, coupled with deeper insights into the genetic underpinnings of neurological disorders, drive the development of more sophisticated, accurate, and comprehensive testing methods. This progress not only expands the scope of disorders that can be genetically tested but also enhances the precision and reliability of diagnostics. Moreover, it fuels the discovery of novel genetic markers and potential therapeutic targets, fostering the evolution of personalized medicine in neurology.

Threat:

The complexity of genetic testing methods

Genetic testing techniques, which often involve intricate processes like sequencing, microarray analysis, and interpretation of genetic variations, can be challenging to implement and comprehend. The need for highly specialized equipment, skilled professionals, and extensive bioinformatics analysis can lead to high operational costs, limiting accessibility to advanced testing. Additionally, the intricate nature of these tests may result in errors, data misinterpretation, or misdiagnoses, impacting their reliability and precision. Furthermore, the complexity of genetic testing can deter healthcare providers and patients from embracing these diagnostic tools, particularly in regions with limited technological infrastructure or healthcare expertise.

COVID-19 Impact:

The COVID-19 pandemic significantly impacted the market, driving both challenges and opportunities. While initial disruptions in supply chains and clinical operations affected testing accessibility, the urgency to understand neurological implications of the virus accelerated research and development in neurogenetics. Telehealth and remote testing gained prominence, facilitating patient access and diagnosis. This period underscored the importance of genetic testing in neurological disorders, prompting increased investment and innovation in testing technologies. Despite initial setbacks, the pandemic spurred advancements and a broader recognition of the critical role neurogenetic testing plays in healthcare, potentially reshaping the market's future landscape.

The polymerase chain reaction (PCR) tests segment is expected to be the largest during the forecast period

The polymerase chain reaction (PCR) test has a significant share in the market. PCR's ability to amplify DNA segments aids in detecting mutations linked to disorders like Huntington's disease or Parkinson's. Its high specificity and sensitivity empower accurate analysis of genetic markers, crucial in early diagnosis and disease monitoring. PCR's role extends to research, drug development, and personalized medicine within neurology, driving advancements in understanding the genetic basis of conditions. As a foundational tool, PCR tests continue to revolutionize neurogenetic testing, fostering insights that shape both research and clinical approaches.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospital has the highest CAGR within the market over the forecast period. They offer access to sophisticated testing facilities, allowing comprehensive genetic screenings, aiding in the identification of neurogenetic disorders. These institutions integrate testing into their diagnostic pathways, facilitating early disease detection and personalized treatment strategies. Hospitals also serve as centers for multidisciplinary collaboration, bringing together geneticists, neurologists, and other specialists to provide holistic care, contributing to ongoing research, and implementing cutting-edge testing methodologies, thereby significantly shaping the landscape of neurogenetic testing.

Region with largest share:

North America holds a significant position and expected to hold a largest share over the forecast period. The region houses leading biotech and pharmaceutical companies, fostering innovation and driving the development of cutting-edge testing methodologies. With a high prevalence of neurological disorders and a proactive healthcare system, North America witnesses extensive adoption of neurogenetic testing across clinical and research domains. The market in this region is characterized by a strong regulatory framework, strategic collaborations between academic institutions and industry, and a growing emphasis on personalized medicine, solidifying North America's position at the forefront of neurogenetic testing advancements.

Region with highest CAGR:

The Asia Pacific region witnessed highest CAGR in the market. With a large and diverse population, this region encounters a notable burden of neurological disorders, propelling the need for advanced diagnostic solutions. Furthermore, the presence of emerging economies and supportive government initiatives fosters collaborations between industry and research institutions, paving the way for expanded accessibility to testing and fueling the evolution of tailored approaches for diagnosing and managing neurological conditions in the Asia Pacific.

Key players in the market

Some of the key players in Neurogenetic Testing Market include: Invitae Corporation, Ambry Genetics, PerkinElmer, GeneDx, Centogene, Blueprint Genetics, Genomic Health (Exact Sciences), Fulgent Genetics, QIAGEN and Baylor Genetics.

Key Developments:

In April 2023, Ambry Genetics and LifeStrands Genomics had collaborated to provide clinical genetic testing services in Singapore. Together, they have been chosen to support the Clinical Implementation Pilots (CIPs) for Phase II of Singapore's National Precision Medicine (NPM) programme through an open tender commissioned by Precision Health Research, Singapore (PRECISE) - the central entity implementing NPM.

In April 2023, Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that it will present new data highlighting the company's novel technology and approaches to early cancer detection at the American Association for Cancer Research® (AACR) Annual Meeting 2023 in Orlando, Florida.

In August 2022, PerkinElmer has signed an agreement with private equity firm New Mountain Capital for the sale of its Applied, Food and Enterprise Services businesses for $2.45bn in cash to allow the company to focus on its high-margin Life Science and Diagnostics businesses.

Types Covered:

• Microarray Analysis
• Whole-Exome Sequencing (WES)
• Multiplex Ligation Dependent Probe Amplification (MLPA)
• Polymerase Chain Reaction (PCR) Tests
• Other Types

End Users Covered:

• Hospitals
• Specialty Clinics
• Research Institutes
• Diagnostics Laboratories
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Neurogenetic Testing Market, By Type

• 5.1 Introduction
• 5.2 Microarray Analysis
• 5.3 Whole-Exome Sequencing (WES)
• 5.4 Multiplex Ligation Dependent Probe Amplification (MLPA)
• 5.5 Polymerase Chain Reaction (PCR) Tests
• 5.6 Other Types

6 Global Neurogenetic Testing Market, By End User

• 6.1 Introduction
• 6.2 Hospitals
• 6.3 Specialty Clinics
• 6.4 Research Institutes
• 6.5 Diagnostics Laboratories
• 6.6 Other End Users

7 Global Neurogenetic Testing Market, By Geography

• 7.1 Introduction
• 7.2 North America
  • 7.2.1 US
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 Italy
  • 7.3.4 France
  • 7.3.5 Spain
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 Japan
  • 7.4.2 China
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 New Zealand
  • 7.4.6 South Korea
  • 7.4.7 Rest of Asia Pacific
• 7.5 South America
  • 7.5.1 Argentina
  • 7.5.2 Brazil
  • 7.5.3 Chile
  • 7.5.4 Rest of South America
• 7.6 Middle East & Africa
  • 7.6.1 Saudi Arabia
  • 7.6.2 UAE
  • 7.6.3 Qatar
  • 7.6.4 South Africa
  • 7.6.5 Rest of Middle East & Africa

8 Key Developments

• 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 8.2 Acquisitions & Mergers
• 8.3 New Product Launch
• 8.4 Expansions
• 8.5 Other Key Strategies

9 Company Profiling

• 9.1 Invitae Corporation
• 9.2 Ambry Genetics
• 9.3 PerkinElmer
• 9.4 GeneDx
• 9.5 Centogene
• 9.6 Blueprint Genetics
• 9.7 Genomic Health (Exact Sciences)
• 9.8 Fulgent Genetics
• 9.9 QIAGEN
• 9.10 Baylor Genetics